Biote Corp

biote Corp. is a woman-led company, which engages in providing bio identical hormone pellet therapy. It delivers a comprehensive, end-to-end platform that provides practitioners with medical education, training and certification, practice management software, and digital and point-of-care marketing support. The company is headquartered in Irving, TX.

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Biote Corp reports robust Q2 earnings, eyes men's health market

Biote Corp's Q2 2023 earnings call highlighted strong financial and strategic progress, marked by revenue growth, improved operating income, and a focus on expanding into new markets. While facing realignment challenges, the company remains confident in its outlook for continued growth and is dedicated to offering innovative wellness solutions.

Biote Corp reports revenue growth and plans nationwide wellness launch

Biote Corp (BTMD) demonstrated positive financial performance in Q3 2023 with revenue growth and improved EBITDA margin, driven by dietary supplements and procedures.
The company's strategic focus on expanding product offerings, engaging with key opinion leaders, and realigning sales territories positions them for future growth.
While facing challenges in procedure revenue growth and market dynamics, Biote Corp's initiatives to launch new offerings and target men's health present opportunities for expansion.

Biote Corp reports robust 2023 growth and targets strategic expansion

Biote Corp (BTMD) delivered strong financial performance in 2023 and sets ambitious targets for 2024, focusing on growth and efficiency.
The company's strategic initiatives, including new offerings and acquisitions, position it well for expansion and market leadership.
Challenges lie in optimizing operations and integration efforts, but Biote's commitment to innovation and growth bodes well for the future.

Biote Corp reports revenue growth and strategic acquisitions in Q1

Biote Corp (BTMD) delivered a solid performance in Q1 2024, marked by revenue growth, improved EBITDA, and strategic acquisitions.
While challenges like declining dietary supplement revenue and analyst inquiries exist, the company's strengths in product innovation and financial outlook bode well for future growth.
By capitalizing on opportunities in product development, geographic expansion, and market demand for wellness solutions, Biote Corp can further solidify its position in the industry.

Biote Corp reports solid Q3 earnings, eyes growth opportunities

Biote Corp (BTMD) delivered strong financial performance in Q3 2024, driven by revenue growth and operational efficiency.
While facing temporary challenges, the company remains focused on growth opportunities through market expansion and operational enhancements.
With a strategic focus on top-tier accounts, practitioner training, and technology integration, Biote is poised for continued success and profitability.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

biote Corp. is a woman-led company, which engages in providing bio identical hormone pellet therapy. It delivers a comprehensive, end-to-end platform that provides practitioners with medical education, training and certification, practice management software, and digital and point-of-care marketing support. The company was founded in 2012 and is headquartered in Irving, TX.

Biote Corp. (BTMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: biote Corp. (BTMD) Q1 Earnings Expected to Decline

IRVING, Texas--(BUSINESS WIRE)--biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced it has entered into a definitive settlement agreement (the “Settlement Agreement”) that concludes outstanding litigation with Dr. Gary S. Donovitz (“Donovitz”), founder and stockholder of Biote. The Settlement Agreement includes a mutual release of all clai.

Biote Announces Definitive Settlement with Founder

IRVING, Texas--(BUSINESS WIRE)--biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced the Company will provide first quarter financial results on Tuesday, May 7, 2024, after the close of the market. A conference call to discuss the firm's results will be held at 5:00 p.m. ET. the same day. Conference Call Details The conference call may be a.

Biote Schedules First Quarter 2024 Financial Results Release and Conference Call

Pfizer

Progyny

VistaGen Therapeutics

Dare Bioscience

Menopause is among the female health conditions with the highest unmet need and has 'enormous potential for innovative treatments,' according to McKinsey.

This overlooked corner of women's health could be a $350 billion market opportunity

biote Corp. (BTMD) Q4 2023 Earnings Call Transcript

IRVING, Texas--(BUSINESS WIRE)--Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced financial results for the fourth quarter and full year ended December 31, 2023. Fourth Quarter 2023 Financial Highlights (All financial result comparisons made are against the prior-year period) Revenue of $45.7 million, a 2.7% increase and in line with pre-released financial guidance Proc.

Biote Reports Fourth Quarter and Full Year 2023 Financial Results

Analysts Estimate biote Corp. (BTMD) to Report a Decline in Earnings: What to Look Out for

IRVING, Texas--(BUSINESS WIRE)--biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced the Company will provide fourth quarter and full year financial results on Tuesday, March 12, 2024, after the close of the market. A conference call to discuss the firm's results will be held at 5:00 p.m. ET. the same day. Conference Call Details The confer.

Biote Schedules Fourth Quarter and Full Year 2023 Financial Results Release and Conference Call

IRVING, Texas--(BUSINESS WIRE)--biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced it has signed a binding term sheet with Dr. Gary S. Donovitz (“Donovitz”), founder and stockholder of Biote, to resolve outstanding litigation. In connection with this agreement, Biote will repurchase all of the Class A common units of Biote Holdings, LLC (.

Biote Announces Agreement to Resolve Litigation and Repurchase All of Founder's Shares

IRVING, Texas--(BUSINESS WIRE)--biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced that its Board of Directors has approved a $20 million share repurchase program of the Company's common stock. This approval grants Biote's management the authority to repurchase outstanding shares of the Company's common stock, from time to time, in the op.

Biote Announces $20 Million Share Repurchase Authorization

IRVING, Texas--(BUSINESS WIRE)--biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced a definitive agreement to acquire F.H. Investments, Inc., d/b/a Asteria Health, a privately held 503B manufacturer of compounded bioidentical hormones. The company operates an FDA-registered 503B outsourcing facility in Birmingham, Alabama and currently sup.

Biote to Purchase Asteria Health

IRVING, Texas--(BUSINESS WIRE)--biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced that management expects 2023 revenue and Adjusted EBITDA to be slightly below prior guidance. The Company had previously forecast that revenue and Adjusted EBITDA would be toward the lower end of the previously announced ranges of $190-$200 million and $56-.

Biote Provides Preliminary 2023 Results and Initial 2024 Guidance

IRVING, Texas--(BUSINESS WIRE)--biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced that Robert Peterson has been named Chief Financial Officer, effective January 8, 2024. Mr. Peterson will lead Biote's finance operations, including accounting and controllership, financial planning and analysis, financial reporting, internal audit, tax, tr.

Biote Names Robert Peterson as Chief Financial Officer

biote Corp. returned to profitability in Q3 2023 and is expected to continue to be profitable in the future. The company's growth is driven by the sale of hormone replacement therapy products and its expansion into complementary wellness products. BTMD is considered undervalued and has an aggressive price target for the end of next year.

biote Should Keep Delivering Strong Growth

Biote Corp. (BTMD) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of $0.08. This compares to loss of $0.09 per share a year ago.

Biote Corp. (BTMD) Reports Q3 Loss, Lags Revenue Estimates

IRVING, Texas--(BUSINESS WIRE)--Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone therapy, today announced financial results for the third quarter ended September 30, 2023. Third Quarter 2023 Financial Highlights (All financial result comparisons made are against the prior year period) Revenue of $45.6 million, an 8.5% increase Gross profit margin of 68.9%, a 70-basis point increase Net income of $19.6 million, representing.

Biote Reports Third Quarter 2023 Financial Results

IRVING, Texas--(BUSINESS WIRE)--biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading provider of hormone optimization, today announced the Company will provide third quarter financial results on Tuesday, November 7, 2023, after the close of the market. A conference call to discuss the firm's results will be held Wednesday, November 8, 2023, at 8:30 a.m. ET. Conference Call Details The conference call may be accessed by dialing (844) 481-2820 (U.S toll-free) or (412) 317-0679 (Intern.

Biote Schedules Third Quarter 2023 Financial Results Release and Conference Call

Biote Corp. (BTMD) came out with quarterly earnings of $0.44 per share, beating the Zacks Consensus Estimate of $0.10 per share. This compares to earnings of $0.27 per share a year ago.

Biote Corp. (BTMD) Beats Q2 Earnings and Revenue Estimates

IRVING, Texas--(BUSINESS WIRE)--Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone therapy, today announced financial results for the second quarter ended June 30, 2023. Second Quarter 2023 Financial Highlights (All financial result comparisons made are against the prior year period) Revenue of $49.3 million, a 19.1% increase Gross profit margin of 67.9%, a 60-basis point increase Net loss of $(13.1) million and GAAP loss pe.

Biote Reports Second Quarter 2023 Financial Results

IRVING, Texas--(BUSINESS WIRE)--biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading provider of hormone optimization, today announced the Company will provide second quarter financial results on Thursday, August 10, 2023, after the close of the market. A conference call to discuss the firm's results will be held Friday, August 11, 2023, at 8:30 a.m. ET. Conference Call Details The conference call may be accessed by dialing (844) 481-2820 (U.S toll-free) or (412) 317-0679 (Internati.

Biote Schedules Second Quarter 2023 Financial Results Release and Conference Call

The consensus price target hints at a 44.7% upside potential for biote Corp. (BTMD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Believe biote Corp. (BTMD) Could Rally 44.7%: Here's is How to Trade

If you are looking for stocks that are well positioned to maintain their recent uptrend, biote Corp. (BTMD) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Recent Price Trend in biote Corp. (BTMD) is Your Friend, Here's Why

biote Corp. (BTMD) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

biote Corp. (BTMD) Moves 5.3% Higher: Will This Strength Last?

IRVING, Texas--(BUSINESS WIRE)---- $BTMD #antiaging--Biote, a leading provider of hormone optimization, has announced the launch of a dedicated Men's Health Division.

Biote Formalizes Commitment to Men's Hormone Health With Launch of New Men's Health Division

IRVING, Texas--(BUSINESS WIRE)--Biote (NASDAQ: BTMD) (the “Company,” “we” or “us”), a leading solutions provider in preventive healthcare through the delivery of personalized hormone therapy, today announced the expiration and results of its previously announced (i) offer to each holder of its outstanding warrants, each whole warrant exercisable for one share of Class A Common Stock, par value $0.0001 per share (“Common Stock”), of the Company, at an exercise price of $11.50 per share (the “War.

News for Biote Corp Stock (BTMD)